STING start-up STipe first to emerge from Novo incubator

STipe will deploy series A to develop tech to improve the therapeutic window of STING modulators

STipe, the first company out of Novo’s BioInnovation Initiative, raised €20 million ($21.9 million) in a series A round to develop technology designed to improve the therapeutic window of STING modulators in the clinic.

Novo Holdings A/S and Arix Biosciences plc (LSE:ARIX) co-led the tranched round, which

Read the full 465 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE